Prof. Christopher Patusky, J.D. is Lead Independent Vice Chairman of the Board of the Company. He has more than 25 years of experience in the private, public and nonprofit sectors. After graduating from The Harvard Law School, he …
In 1Q18, United Therapeutics’ (UTHR) Remodulin generated revenues of $127 million compared to $145.8 million in 1Q17. That was a 13% decline YoY (year-over-year) and a 30% decline quarter-over-quarter.
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put United Therapeutics Corporation UTHR stock into this equation and find out if it …